There are days when we feel for wine drinking friends in France. Yes, Sanofi (NYSE: SNY) has a host of issues and until yesterday did not have leader. A job which now belongs to Stefan Oelrich, who will be the third new leader of this unit over the last two years. Now we would like to believe that the third time will be a charm but this is Sanofi.
The company was hit with another blow when UnitedHealth announced their 2018 formulary which excluded both Lantus and Toujeo, ouch and double ouch.
The real question is just what can Stefan . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.